viruslik
particl
vlp
class
subunit
vaccin
differenti
solubl
recombin
antigen
stronger
protect
immunogen
associ
vlp
structur
like
parent
virus
vlp
either
nonenvelop
envelop
form
follow
express
one
sever
viral
structur
protein
recombin
heterolog
system
depend
complex
vlp
produc
either
prokaryot
eukaryot
express
system
use
targetencod
recombin
vector
case
assembl
cellfre
condit
date
wide
varieti
vlpbase
candid
vaccin
target
variou
viral
bacteri
parasit
fungal
pathogen
well
noninfecti
diseas
produc
differ
express
system
vlp
enter
clinic
develop
licens
commerci
articl
review
vlpbase
vaccin
produc
differ
system
immunogen
anim
model
statu
clinic
develop
date
vaccin
remain
effect
way
control
prevent
infecti
diseas
major
vaccin
current
avail
base
inactiv
live
attenu
pathogen
although
vaccin
highli
effect
smallpox
human
rinderpest
cattl
even
led
erad
target
pathogen
often
induc
side
effect
vlp
form
structur
viral
protein
inher
properti
selfassembl
mimic
morpholog
pathogen
contrast
live
virus
vlp
noninfect
nonrepl
sinc
essenti
devoid
infecti
genet
materi
vlp
display
antigen
epitop
correct
conform
highli
repetit
manner
lead
crosslink
b
cell
immunoglobulin
receptor
b
cell
activ
exogen
antigen
vlp
effici
taken
profession
antigen
present
cell
particularli
dendrit
cell
dc
follow
antigen
process
present
mhc
class
ii
molecul
dc
activ
matur
upregul
costimulatori
molecul
cytokin
product
stimul
helper
cell
lead
induct
strong
humor
cellular
immun
respons
similar
nativ
virus
vlp
process
cytosol
dc
present
mhc
class
molecul
cytotox
cell
crosspresent
mechan
induc
potent
cytotox
immun
respons
thu
far
vlp
shown
highli
immunogen
recent
come
focu
divers
applic
vaccin
target
drug
deliveri
gene
therapi
immun
therapi
four
recombin
vaccin
market
glaxosmithklin
gsk
engerix
hepat
b
viru
hbv
cervarix
human
papillomaviru
hpv
merck
co
inc
recombivax
hb
hbv
gardasil
hpv
base
highli
purifi
vlp
addit
number
vlpbase
vaccin
candid
includ
gsk
antimalaria
vaccin
rt
clinic
develop
mani
other
target
pathogen
influenza
viru
rotaviru
rv
human
immunodefici
viru
hiv
undergo
preclin
evalu
date
vlp
nonenvelop
envelop
produc
number
target
use
mammalian
plant
insect
yeast
bacteri
cell
cellfre
platform
addit
vaccin
antigen
produc
genet
fusion
chemic
conjug
viral
structur
protein
result
chimer
vlp
key
aspect
licens
advanc
stage
vlp
vaccin
present
tabl
review
focus
differ
approach
design
engin
product
develop
vlpbase
vaccin
base
structur
parent
virus
vlp
divid
two
major
categori
nonenvelop
vlp
envelop
vlp
nonenvelop
vlp
typic
compos
one
compon
pathogen
abil
selfassembl
particl
includ
host
compon
fig
approach
use
develop
vaccin
pathogen
hpv
rv
nonenvelop
vlp
continu
explor
prefer
approach
develop
suv
number
pathogen
includ
canin
mink
porcin
parvovirus
use
protein
express
insect
cell
norwalk
viru
nv
use
selfassembl
kda
capsid
protein
produc
vitro
transcriptiontransl
baculoviru
recombin
express
system
vlp
hepat
e
viru
hev
result
selfassembl
kda
ntermin
truncat
capsid
protein
viru
express
insect
cell
shown
highli
immunogen
vlp
form
hbv
surfac
antigen
hbsag
somewhat
differ
typic
nonenvelop
vlp
due
high
content
host
cell
lipid
specif
acid
phospholipid
shown
interact
hbsag
facilit
conformationl
integr
antigen
hbsag
tend
assembl
watersolubl
micel
associ
endoplasm
reticulum
er
origin
lipid
use
recombin
dna
technolog
hbsag
success
produc
yeast
mammalian
cell
express
system
result
vlp
similar
highli
immunogen
hbsag
subvir
particl
isol
plasma
individu
chronic
infect
hbv
recombin
hbsag
vlp
vari
molecular
weight
size
monom
composit
glycosyl
immunogen
well
site
assembl
detail
see
section
approach
develop
engin
produc
chimer
nonenvelop
vlp
vaccin
target
express
fusion
partner
surfac
particl
consist
compon
anim
plant
pathogen
abil
selfassembl
carrier
fig
exampl
antimalaria
vaccin
rt
base
malaria
antigen
express
fusion
partner
surfac
vlp
contain
hbsag
last
two
decad
coat
protein
cp
sever
plant
virus
success
engin
produc
target
antigen
rang
mammalian
pathogen
exampl
chimer
particl
form
cp
tobacco
mosaic
viru
tmv
fuse
plasmodium
falciparum
epitop
alfalfa
mosaic
viru
almv
present
rabi
viru
respiratori
syncyti
viru
rsv
epitop
cowpea
mosaic
viru
cpmv
display
epitop
bacillu
anthraci
p
falciparum
potato
viru
x
pvx
carri
epitop
influenza
viru
shown
stimul
targetspecif
immun
respons
structur
complex
nonenvelop
vlp
contain
multipl
interact
viral
capsid
protein
organ
sever
concentr
layer
repres
vlp
engin
virus
famili
reovirida
icosahedr
virion
bluetongu
viru
contain
seven
capsid
protein
howev
four
necessari
vlp
format
bluetongu
vlp
contain
two
four
major
capsid
protein
produc
insect
cell
use
baculoviru
express
vector
stabl
doublelay
triplelay
rv
vlp
produc
coexpress
differ
combin
major
structur
protein
rv
insect
cell
rv
vlp
maintain
structur
function
characterist
nativ
viru
particl
well
interact
summari
nonenvelop
vlp
consist
singl
multipl
compon
target
pathogen
singl
multipl
vaccin
target
antigen
display
vlp
surfac
fusion
heterolog
viral
protein
abil
selfassembl
envelop
vlp
rel
complex
structur
consist
host
cell
membran
envelop
integr
target
antigen
display
outer
surfac
fig
envelop
vlp
provid
higher
degre
flexibl
integr
antigen
heterolog
pathogen
promin
exampl
envelop
vlp
vlp
engin
express
vaccin
target
antigen
influenza
virus
retrovirus
hepat
c
viru
hcv
product
envelop
vlp
requir
coexpress
sever
structur
viral
protein
assembl
particl
incorpor
host
membran
releas
particl
bud
cell
membran
exampl
success
assembl
bud
influenza
vlp
achiev
coexpress
four
structur
protein
hemagglutinin
ha
neuraminidas
na
matrix
protein
ion
channel
protein
viru
result
vlp
produc
insect
cell
close
resembl
nativ
influenza
viru
particl
size
morpholog
fine
structur
surfac
spike
express
protein
alon
ha
na
nucleocapsid
protein
np
result
format
releas
particl
studi
use
baculovirusand
vaccinia
virusbas
express
system
influenza
vlp
contain
ha
na
ha
produc
support
key
role
protein
envelop
vlp
format
releas
contrast
recent
studi
chen
et
al
use
plasmid
dnatransfect
mammalian
cell
demonstr
assembl
bud
influenza
vlp
compris
ha
na
addit
influenza
vlp
correct
assembl
releas
envelop
vlp
report
retrovirus
includ
hiv
simian
immunodefici
viru
siv
whose
gag
protein
shown
form
vlp
insect
cell
moreov
envelop
vlp
contain
target
antigen
heterolog
virus
siv
gag
protein
hiv
env
protein
produc
furthermor
express
insect
cell
hcv
core
protein
envelop
protein
protein
shown
result
format
releas
envelop
vlp
nm
diamet
presum
deriv
er
morpholog
immunoreact
biophys
characterist
hcv
vlp
similar
put
hcv
virion
isol
hcvinfect
human
result
also
suggest
hcv
core
envelop
protein
suffici
vlp
assembl
protein
requir
envelop
vlp
approach
increasingli
use
produc
recombin
suv
report
effici
assembl
releas
insect
cell
human
sever
acut
respiratori
syndrom
coronaviru
sar
cov
like
particl
express
e
protein
suffici
smoothsurfac
vlp
assembl
highlevel
accumul
coexpress
e
protein
sarscov
singl
baculoviru
vector
result
effici
format
vlp
morpholog
mimic
nativ
sarscov
virion
also
matrix
protein
ebola
viru
shown
form
vlp
produc
mammalian
cell
could
potenti
vaccin
prevent
infect
ebola
viru
inclus
ebola
viru
protein
np
gp
enhanc
vlp
format
approxim
without
major
chang
vlp
morpholog
anoth
exampl
envelop
vlp
vlp
newcastl
diseas
viru
ndv
consist
hana
hn
fusion
f
np
protein
viru
vlp
produc
avian
cell
structur
function
resembl
ndv
virion
preserv
biolog
activ
vlpassoci
ndv
glycoprotein
releas
effici
allow
prepar
larg
quantiti
particl
need
vaccin
manufactur
recent
studi
demonstr
util
plant
anoth
altern
produc
vlpbase
vaccin
anim
pathogen
conclus
envelop
vlp
repres
complex
structur
consist
multipl
compon
target
pathogen
host
membran
compon
resembl
pathogen
vlpbase
vaccin
safe
immunogen
testimoni
fact
current
licens
recombin
suv
base
vlp
envelop
nonenvelop
vlp
effici
gener
humor
cellmedi
immun
respons
differ
cell
substrat
includ
bacteri
yeast
insect
mammalian
plant
express
system
use
produc
vlp
bacteria
wide
use
express
system
manufactur
recombin
protein
prefer
platform
vlp
product
due
number
factor
includ
absenc
mammalianlik
posttransl
modif
ptm
system
nevertheless
bacteria
use
produc
nonenvelop
vlp
base
compon
pathogen
abil
selfassembl
bacteri
host
fusion
vaccin
target
antigen
bacteriophag
surfac
protein
mani
type
sexual
transmit
hpv
type
highestrisk
carcinogen
type
caus
cervic
cancer
relat
genit
neoplasia
bacteriaderiv
hpv
vlp
produc
express
major
capsid
protein
hpv
type
also
intracellular
assembl
vlp
document
lactobacillu
casei
lactoseinduc
express
system
vlp
shown
display
conform
epitop
elicit
serum
antibodi
mice
sominskaya
et
al
hand
engin
produc
escherichia
coli
chimer
vlp
consist
hbv
core
antigen
hbcag
use
carrier
hbv
hcv
highli
conserv
ntermin
core
epitop
antigen
mice
immun
bival
chimer
vlp
gener
hightit
antibodi
respons
cytotox
lymphocyt
ctl
respons
specif
target
vlp
also
gener
follow
express
truncat
version
hcv
core
antigen
hccag
consist
ntermin
amino
acid
e
coli
averag
diamet
nm
similarli
hcv
epitop
fuse
cterminu
papaya
mosaic
viru
papmv
cp
follow
express
e
coli
assembl
chimer
papmv
vlp
anoth
studi
papmv
cp
use
produc
chimer
vlp
display
lymphocyt
choriomening
viru
lcmv
immunodomin
ctl
epitop
chimer
papmvhcv
vlpvaccin
mice
develop
longlast
day
epitopespecif
antibodi
respons
papmvlcmv
vlp
induc
matur
dendrit
cell
effici
process
crosspres
epitop
ctl
vitro
vivo
protect
immun
mice
lcmv
challeng
anoth
exampl
chimer
nonenvelop
vlp
malaria
vaccin
candid
engin
produc
e
coli
apovia
inc
san
diego
ca
chimer
vlp
consist
recombin
hbcag
carri
genet
fuse
central
repeat
region
p
falciparum
circumsporozoit
protein
csp
contain
immunodomin
b
cell
epitop
hlarestrict
cell
epitop
univers
cell
epitop
vaccin
malarivax
shown
elicit
anticsp
antibodi
mice
monkey
cspspecif
cell
respons
mice
vaccin
well
toler
human
gener
cspspecif
antibodi
cellular
immun
respons
vaccine
phase
clinic
trial
administ
presenc
differ
adjuv
tabl
strategi
also
employ
sanofi
pasteur
lyon
franc
develop
univers
influenza
vaccin
base
highli
conserv
epitop
human
avian
influenza
virus
display
surfac
hbcag
vlp
anim
immun
parenter
intranas
chimer
vlp
protect
lethal
challeng
variou
influenza
viru
subtyp
protect
enhanc
use
adjuv
correl
higher
antibodi
respons
immunogen
hbcag
vlpbase
vaccin
confirm
phase
clinic
trial
tabl
sever
group
focus
develop
bacteriophagebas
vlp
vaccin
exampl
cyto
biotechnolog
ag
zurichschlieren
switzerland
develop
number
vlp
vaccin
candid
base
rna
bacteriophag
chimer
vlp
vaccin
target
selfantigen
direct
noninfecti
diseas
allergi
neurodegen
alzheim
diseas
autoimmun
disord
type
ii
diabet
mellitu
cancer
melanoma
hypertens
nicotin
tabl
candid
vaccin
alzheim
diseas
design
present
chemic
coupl
peptid
deriv
ntermin
b
cell
epitop
amyloid
beta
protein
main
compon
amyloid
plaqu
found
brain
patient
alzheim
diseas
surfac
vlp
form
cp
vaccin
shown
induc
igg
antibodi
reduc
amyloid
accumul
transgen
mice
rhesu
monkey
express
precursor
protein
without
stimul
cell
caus
microhaemorrhag
inflammatori
reaction
amyloidcontain
brain
tissu
random
placebocontrol
trial
patient
mildtomoder
alzheim
diseas
well
toler
induc
meningoenceph
vaccin
patient
develop
substanti
titer
igg
antibodi
exhibit
differ
compar
placebo
cerebrospin
fluid
level
whole
brain
volum
assess
magnet
reson
imag
phase
clinic
trial
ongo
tabl
anoth
vlp
vaccin
candid
direct
hypertens
repres
angiotensin
iideriv
peptid
conjug
cp
vlp
chimer
vlp
elicit
angiotensinspecif
antibodi
reduc
blood
pressur
hypertens
rat
phase
studi
patient
mildtomoder
hypertens
vaccin
administ
subcutan
sc
convent
regimen
inject
week
found
well
toler
significantli
reduc
blood
pressur
daytim
especi
morn
compar
placebo
vaccin
evalu
two
independ
trial
use
altern
regimen
inject
week
attempt
elicit
higher
antibodi
titer
lead
stronger
reduct
blood
pressur
although
vaccin
elicit
higher
antibodi
titer
compar
first
studi
due
low
affin
antibodi
extent
decreas
blood
pressur
signific
compar
placebo
thu
higher
dose
vaccin
mg
vs
mg
found
efficaci
panel
chimer
vlp
vaccin
candid
also
develop
base
rna
bacteriophag
display
peptid
selfantigen
angiotensin
ii
gonadotropin
releas
hormon
pathogen
salmonella
typhi
outer
membran
protein
hiv
nef
influenza
protein
fuse
either
cterminu
cp
vlp
highli
immunogen
mice
influenza
vlp
induc
strong
rapidonset
antibodi
respons
complet
protect
lethal
influenza
viru
challeng
vlp
format
e
coli
structur
protein
also
document
murin
polyomaviru
simian
papovaviru
furthermor
cowpea
chlorot
mottl
viru
cp
shown
express
selfassembl
nativ
viruslik
vlp
pseudomona
fluorescen
suggest
potenti
use
cp
vaccin
carrier
howev
foreign
epitop
report
introduc
vlp
yeast
wellestablish
platform
recombin
protein
express
continu
use
vlp
product
two
merck
co
inc
licens
vlpbase
vaccin
recombivax
hb
gardasil
manufactur
use
system
despit
success
system
limit
differ
mammalian
cell
ptm
protein
particularli
protein
glycosyl
due
limit
system
gener
use
product
nonenvelop
vlp
nevertheless
product
envelop
vlp
yeast
use
saccharomyc
cerevisia
spheroplast
achiev
releas
spheric
vlp
encapsul
yeast
cell
plasma
membran
morpholog
resembl
immatur
hiv
particl
yeastderiv
hiv
vlp
effici
taken
dc
vitro
via
macropinocytosi
endocytosi
mediat
mannoserecogn
receptor
mannos
receptor
induc
dc
matur
secret
dc
matur
also
enhanc
yeast
membran
compon
like
via
tolllik
receptor
signal
contribut
stimul
gagspecif
immun
respons
furthermor
dc
load
yeastderiv
hiv
vlp
shown
convert
gagspecif
memori
cell
effector
cell
chronic
hivinfect
individu
via
crosspresent
although
gagspecif
cell
popul
patient
remain
unrespons
altern
vlp
vaccin
candid
produc
yeast
chimer
nonenvelop
vlp
fuse
protein
protein
cerevisia
retrotransposon
ty
result
ty
chimer
vlp
elicit
hivspecif
serum
antibodi
rabbit
immunogen
evalu
prophylact
clinic
studi
effect
therapeut
vaccin
tabl
number
studi
demonstr
express
selfassembl
hpv
protein
vlp
yeast
hpv
vlp
shown
immunogen
mice
also
induc
system
mucos
neutral
antibodi
well
cytokin
respons
vaccin
nonhuman
primat
furthermor
proofofprincipl
studi
cottontail
rabbit
papillomaviru
vlp
produc
cerevisia
success
protect
anim
virusinduc
papilloma
format
first
licens
hpv
vaccin
approv
us
fda
gardasil
merck
usa
quadrival
vaccin
contain
vlp
hpv
type
produc
cerevisia
administ
intramuscularli
im
three
dose
aluminum
hydroxyphosph
sulphat
adjuv
tabl
sever
random
placebocontrol
phase
clinic
trial
evalu
gardasil
demonstr
safeti
strong
immunogen
excel
prophylact
efficaci
persist
hpv
infect
genit
diseas
associ
four
type
hpv
present
vaccin
young
uninfect
women
cp
noroviru
nv
lead
etiolog
caus
outbreak
nonbacteri
gastroenter
human
express
pichia
pastori
also
demonstr
selfassembl
vlp
oral
immun
mice
raw
yeast
extract
contain
vlp
stimul
system
mucos
immun
respons
similar
approach
product
vlp
consist
structur
protein
rv
common
caus
sever
gastroenter
infant
young
children
worldwid
cerevisia
achiev
optim
molecular
process
strategi
repres
first
report
coexpress
three
rv
protein
assembl
multilay
vlp
one
antigen
frequent
use
vlpbase
vaccin
product
hbsag
hbsag
express
p
pastori
cerevisia
hansenula
polymorpha
although
highlevel
retent
accumul
hbsag
er
document
neither
secret
protein
intracellular
vlp
format
observ
suggest
vlp
assembl
took
place
downstream
process
yeast
biomass
number
hepat
b
vaccin
licens
worldwid
base
hbsag
proteinform
vlp
express
yeast
includ
us
fdaapprov
engerixb
gsk
belgium
recombivax
hb
merck
usa
manufactur
cerevisia
gener
potent
protect
antihepat
b
antibodi
respons
tabl
anoth
hbsag
vlpbase
vaccin
candid
malaria
csp
antigen
fuse
hbsag
undergo
clinic
develop
gsk
rixensart
belgium
along
path
malaria
vaccin
initi
bill
melinda
gate
foundat
manufactur
malaria
vlp
vaccin
candid
rt
produc
mixtur
nativ
hbsag
chimer
hbsag
contain
acid
fragment
csp
cerevisia
clinic
efficaci
adjuv
rt
vaccin
protect
experiment
challeng
p
falciparum
sporozoit
healthi
adult
protect
clinic
sever
malaria
young
childrenha
demonstr
sever
trial
tabl
similarli
vlp
consist
entir
hccag
produc
methylotroph
yeast
p
pastori
demonstr
resembl
authent
hcv
nucleocapsid
particl
matur
stage
judg
size
morpholog
specif
recogn
serum
chronic
hcv
carrier
patient
p
pastori
express
system
base
constitut
promot
dehydrogenas
use
highlevel
express
premembran
envelop
e
glycoprotein
dengu
viru
type
hbsag
lead
assembl
releas
vlp
similar
authent
virion
confirm
electron
microscopi
em
immun
mice
vlp
shown
induc
strong
antibodi
respons
neutral
activ
similar
titer
achiev
follow
immun
inactiv
viru
vlp
form
selfassembl
cerevisia
gag
protein
noninfecti
dsrna
mycoviru
la
also
exploit
vaccin
platform
display
ctermin
fuse
truncat
immunodomin
protein
human
cytomegaloviru
hcmv
insid
particl
test
vitro
chimer
vlp
abl
activ
antigenspecif
memori
cell
blood
cell
collect
hcmvposit
donor
suggest
epitop
crosspresent
mhc
class
pathway
protein
polyomavirus
human
jc
polyomaviru
serotyp
sb
bk
polyomaviru
rhesu
monkey
hamster
hamster
polyomaviru
mice
murin
polyomaviru
bird
budgerigar
fledgl
diseas
viru
goos
hemorrhag
polyomaviru
also
express
high
level
cerevisia
shown
vari
crossreact
heterolog
mous
rabbit
sera
abil
caus
hemagglutin
erythrocyt
anoth
system
extens
util
vlp
product
baculovirusinsect
cell
express
system
similar
yeast
insect
cell
use
produc
number
vlpbase
vaccin
particular
one
current
hpv
vaccin
cervarix
insect
cell
use
manufactur
nonenvelop
envelop
vlp
envelop
vlp
vaccin
produc
insect
cell
among
advanc
clinic
develop
insect
cell
system
possess
eukaryotictyp
ptm
includ
glycosyl
accommod
highlevel
accumul
foreign
protein
lack
mammalian
pathogen
contamin
target
coproduc
envelop
baculoviru
particl
main
limit
system
requir
develop
complex
scheme
vlp
purif
insect
cellproduc
vlp
target
develop
vaccin
hiv
express
recombin
baculovirusinfect
spodoptera
frugiperda
sf
deriv
cell
precursor
polyprotein
selfassembl
larg
envelop
vlp
highli
immunogen
elicit
innat
acquir
immun
respons
particular
vlp
induc
potent
longliv
month
gagspecif
ctl
respons
multipl
natur
process
epitop
nonhuman
primat
cellular
immun
respons
substanti
enhanc
gag
vlp
administ
mice
baboon
boost
prime
gag
dna
vaccin
addit
baboon
primeboost
vaccin
induc
high
titer
serum
antibodi
severalfold
higher
induc
singl
administr
dna
vaccin
vlp
addit
abil
gag
protein
serv
antigen
carrier
util
construct
variou
chimer
vlp
express
antigen
fuse
nonstructur
hiv
env
aim
broaden
immun
respons
chimer
gag
vlp
produc
use
baculoviru
vector
contain
glycoprotein
domain
nef
pol
revers
transcriptas
rt
tat
nef
protein
furthermor
coexpress
furin
along
siv
result
incorpor
cleavag
product
env
assembl
vlp
fuse
antigen
employ
chimer
vlp
approach
broaden
breadth
magnitud
immun
respons
chimer
hiv
vlp
carri
either
whole
protein
domain
third
variabl
domain
absenc
adjuv
shown
rais
strong
antibodi
respons
neutral
antibodi
respons
potent
ctl
respons
epitop
locat
domain
mice
immun
rhesu
macaqu
chimer
simianhuman
immunodefici
viru
shiv
vlp
contain
siv
protein
gener
neutral
antibodi
cellular
immun
respons
result
acceler
viral
clearanc
monkey
infect
compar
nonvaccin
control
vlp
carri
region
induc
antibodi
neutral
activ
rabbit
strong
epitopespecif
ctl
respons
dna
prime
follow
boost
chimer
vlp
express
rt
tat
nef
induc
strong
broad
gagand
rtspecif
cellular
immun
respons
mice
twoto
threefold
greater
two
administr
dna
vaccin
stimul
antigenspecif
cell
contrast
nonchimer
gag
vlp
induc
predominantli
robust
gagspecif
cell
respons
vlp
express
hiv
env
glycoprotein
nativ
trimer
conform
elicit
neutral
antibodi
respons
combin
sera
synergist
effect
neutral
hiv
pseudovirus
immunogen
vlp
also
enhanc
incorpor
immunostimulatori
adhes
molecul
cytokin
exampl
membranebound
ligand
express
surfac
siv
vlp
target
activ
dc
via
interact
aim
enhanc
cell
respons
activ
vlp
monitor
record
increas
cytokin
product
dc
vitro
enhanc
level
humor
cellular
immun
respons
protein
immun
mice
effect
observ
immun
mice
anoth
studi
chimer
siv
vlp
contain
gag
env
membraneanchor
granulocytemacrophag
colonystimul
factor
gmcsf
gener
use
immun
mice
significantli
enhanc
product
siv
envspecif
antibodi
neutral
activ
cell
respons
comparison
nonchimer
siv
vlp
siv
vlp
contain
nonchimer
siv
vlp
mix
solubl
gmcsf
nonchimer
siv
vlp
insect
cell
equal
effect
produc
nonenvelop
vlp
express
plu
protein
baculovirusinfect
insect
cell
demonstr
result
success
selfassembl
vlp
elicit
high
titer
serum
neutral
antibodi
mice
rabbit
follow
im
sc
immun
adjuv
present
furthermor
vlp
shown
induc
system
cellular
immun
mice
administ
oral
presenc
cholera
toxin
cpg
respect
mucos
adjuv
cervarix
manufactur
gsk
belgium
bival
hpv
vlpbase
vaccin
hpv
type
produc
trichoplusia
ni
high
five
tm
insect
cell
approv
us
fda
tabl
similar
situat
gardasil
random
clinic
trial
show
excel
prophylact
efficaci
cervarix
young
women
hpv
typespecif
immunogen
lack
therapeut
efficaci
licens
hpv
vaccin
hpvinfect
individu
attempt
made
develop
crossprotect
therapeut
hpv
vaccin
candid
chimer
vlp
contain
protein
fuse
cterminu
either
truncat
protein
protein
produc
high
five
tm
insect
cell
shown
protect
mice
tumor
challeng
even
absenc
adjuv
protect
appear
mediat
mhc
class
irestrict
ctl
sinc
occur
perforinknockout
mice
contrast
tumor
protect
observ
anim
studi
trend
histolog
improv
observ
patient
highgrad
cervic
intraepitheli
neoplasia
receiv
sc
chimer
vlp
although
humor
cellular
immun
respons
induc
anoth
approach
insert
crossreact
epitop
vlp
found
result
induct
crossneutr
antibodi
type
hpv
immun
rabbit
vlp
consist
kda
nv
cp
similar
nativ
capsid
size
appear
antigen
elicit
high
level
nvspecif
serum
antibodi
mice
rabbit
guinea
pig
follow
im
immun
subsequ
studi
demonstr
oral
immun
nv
cp
vlp
induc
system
mucos
antibodi
respons
mice
oral
administ
nv
cp
vlp
safe
immunogen
human
induc
humor
cellular
immun
respons
sever
clinic
trial
administr
dri
powder
compris
nv
vlp
vaccin
adjuv
monophosphoryl
lipid
mpl
mucoadher
chitosan
ligocyt
pharmaceut
bozeman
mt
shown
well
toler
elicit
antibodi
antibodysecret
cell
express
home
receptor
mucos
peripher
lymphoid
tissu
confer
protect
experiment
human
nv
ill
anoth
phase
clinic
trial
bival
noroviru
vlp
vaccin
formul
contain
mpl
alum
ligocyt
pharmaceut
deliv
via
im
rout
demonstr
highli
immunogen
stimul
igg
iga
antibodi
first
vaccin
dose
tabl
anoth
import
pathogen
target
develop
vlpbase
vaccin
rv
sever
report
demonstr
selfassembl
differ
type
rv
vlp
capsid
protein
express
baculovirusinfect
insect
cell
express
singl
protein
result
format
empti
corelik
particl
coexpress
heterolog
rv
strain
bovin
simian
yield
assembl
doublelay
vlp
central
role
rv
vlp
assembl
confirm
express
differ
combin
vp
protein
character
result
vlp
anoth
studi
doubleand
triplelay
vlp
observ
coexpress
respect
without
triplelay
vlp
morpholog
similar
nativ
rv
virion
vlp
retain
neutral
nonneutr
epitop
well
hemagglutin
activ
doublelay
rv
vlp
deliv
via
oral
im
intraperiton
ip
intrarect
rout
demonstr
induc
system
mucos
immun
respons
confer
protect
rv
challeng
mice
suggest
key
role
protect
immun
rv
contrast
gnotobiot
piglet
model
vlp
adjuv
induc
antibodi
respons
confer
protect
anim
prime
live
attenu
human
rv
protect
rate
determin
reduct
rv
shed
altern
strategi
partial
protect
rv
achiev
vaccin
piglet
adjuv
rv
vlp
contain
antigen
similarli
infect
insect
cell
recombin
baculovirus
encod
hbcag
shown
result
highlevel
express
protein
selfassembl
vlp
sf
cell
assembl
hcv
vlp
insect
cell
achiev
express
hcv
core
protein
envelop
protein
describ
section
immun
hcv
vlp
induc
high
titer
virusspecif
antibodi
virusspecif
cell
respons
mice
baboon
confer
protect
recombin
hcvvaccinia
viru
infect
mice
cell
depend
vlp
compos
c
protein
also
produc
elicit
hcvspecif
serum
antibodi
immun
mice
furthermor
express
ntermin
truncat
version
kda
capsid
protein
hev
shown
result
vlp
assembl
nideriv
cell
releas
vlp
confirm
em
hev
vlp
littl
smaller
nativ
hev
virion
possess
similar
antigen
bound
hevspecif
igg
igm
antibodi
oral
administr
mice
hev
vlp
without
adjuv
gener
system
igg
intestin
iga
antibodi
react
nativ
hev
antigen
cynomolgu
monkey
oral
immun
hev
vlp
induc
system
antibodi
product
protect
infect
hepat
follow
hev
challeng
signific
effort
particularli
last
sever
year
place
develop
vlpbase
influenza
vaccin
describ
section
ahong
vlp
base
selfassembl
influenza
protein
differ
combin
influenza
protein
ha
na
produc
cell
subsequ
studi
report
product
vlp
influenza
strain
includ
highli
pathogen
strain
pandem
avian
influenza
swine
influenza
addit
list
monoval
influenza
vlp
vaccin
bival
vlp
also
prepar
individu
produc
admix
vlp
contain
ha
antigen
influenza
virus
trival
vlp
produc
coexpress
three
ha
subtyp
type
b
influenza
virus
furthermor
coexpress
membraneanchor
form
flagellin
tolllik
receptor
ligand
ha
influenza
result
assembl
vlp
contain
intern
adjuv
compon
insect
cellproduc
influenza
vlp
shown
contain
uncleav
ha
molecul
bind
influenza
vlp
cell
membran
shown
result
vlpcell
fusion
fusogen
ph
vlp
endocytosi
mediat
interact
ha
cell
sialyl
receptor
contribut
vlp
antigen
present
immunogen
influenza
vlp
explor
number
anim
studi
also
evalu
ex
vivo
im
immun
vlp
deriv
influenza
elicit
haspecif
serum
antibodi
titer
compar
induc
subleth
dose
live
viru
complet
protect
lethal
influenza
viru
challeng
vlp
deriv
avian
ahong
strain
given
im
sc
mice
rat
ferret
gener
high
antibodi
titer
detect
enzymelink
immunosorb
assay
elisa
hemagglutinationinhibit
hai
assay
provid
partial
protect
influenza
viru
challeng
immun
vlp
base
influenza
strain
induc
high
serum
mucos
antibodi
titer
includ
neutral
antibodi
homolog
heterolog
virus
mice
protect
lethal
challeng
either
homolog
heterolog
viru
even
five
month
postvaccin
moreov
immun
sera
also
confer
complet
protect
upon
transfer
protect
associ
suppress
proinflammatori
cytokin
releas
similar
longterm
protect
immun
respons
mice
report
vlp
deriv
influenza
viru
vlp
vlp
deriv
influenza
viru
elicit
high
hai
antibodi
titer
provid
highli
effect
protect
lethal
viru
challeng
mice
ferret
singl
dose
vaccin
blind
random
placebocontrol
phase
phase
clinic
trial
unadjuv
vlp
influenza
vaccin
candid
respect
compos
ha
na
manufactur
novavax
inc
rockvil
md
found
safe
well
toler
elicit
robust
hai
neutral
antibodi
respons
healthi
adult
tabl
notabl
antibodi
induc
vlp
shown
crossreact
multipl
clade
avian
influenza
viru
correl
preferenti
antibodi
bind
influenza
ha
trimer
attempt
extrapol
result
anim
studi
human
organ
cultur
human
skin
explant
prepar
evalu
chang
langerhan
cell
lc
follow
intraderm
inject
vlp
contain
ha
influenza
viru
result
demonstr
lc
respond
influenza
vlp
morpholog
chang
migrat
epidermi
attribut
antigeninduc
lc
activ
immunogen
influenza
vlp
vaccin
explor
studi
compar
vlp
recombin
solubl
ha
antigen
inactiv
influenza
viru
im
vaccin
mice
ferret
season
influenza
strain
vlp
gener
stronger
elisa
hai
antibodi
respons
induc
recombin
ha
antigen
inactiv
influenza
viru
antibodi
broader
crossreact
drift
strain
mice
vaccin
vlp
deriv
highli
pathogen
avian
influenza
clade
also
show
stronger
antibodi
respons
compar
recombin
ha
significantli
increas
crossclad
antibodi
reactiv
respons
specif
peptid
well
enhanc
protect
homolog
crossclad
viru
challeng
vlp
also
induc
complet
protect
ferret
lethal
challeng
either
parent
influenza
strain
vlp
demonstr
greater
immunogen
compar
recombin
ha
antigen
vaccin
efficaci
improv
incorpor
intern
adjuv
exampl
flagellincontain
vlp
administ
via
im
rout
elicit
stronger
antibodi
respons
mice
standard
vlp
predominantli
subclass
also
enhanc
greater
cytokin
product
addit
type
vlp
protect
mice
homolog
viru
challeng
flagellincontain
vlp
protect
heterosubtyp
challeng
influenza
aphilippin
viru
anoth
approach
achiev
broad
improv
protect
multipl
subtyp
influenza
viru
construct
vlp
contain
protein
use
supplement
inactiv
influenza
vaccin
thu
recent
studi
inclus
protein
proteinbas
vlp
result
complet
longterm
protect
lethal
challeng
heterolog
heterosubtyp
influenza
virus
includ
swine
influenza
strain
vlp
use
along
inactiv
influenza
vaccin
addit
nativelik
vlp
chimer
retroviru
gagbas
vlp
contain
influenza
protein
also
produc
insect
cell
greater
quantiti
compar
mammalian
cell
system
resembl
retrovirus
size
morpholog
exampl
murin
leukemia
viru
gag
vlp
pseudotyp
ha
na
influenza
strain
shown
highli
immunogen
mice
follow
im
immun
vlp
induc
strong
crossclad
hai
antibodi
respons
mice
ferret
confer
complet
protect
homolog
viru
challeng
notabl
vlp
also
induc
neutral
antibodi
signific
heterosubtyp
protect
ferret
mechan
known
anoth
vlp
sivha
chimera
demonstr
directli
bind
b
cell
vitro
stimul
activ
prolifer
class
switch
recombin
somat
mutat
follow
ip
mous
immun
vlp
induc
germin
center
format
convent
b
cell
prolifer
preferenti
antibodi
product
confirm
result
obtain
vitro
human
rsv
import
caus
acut
respiratori
infect
infant
children
well
elderli
immunocompromis
adult
potenti
vaccin
develop
chimer
rsv
vlp
prepar
express
influenza
viru
matrix
protein
core
display
f
g
protein
rsv
surfac
shown
induc
rsvspecif
antibodi
respons
serum
lung
provid
effect
protect
infect
im
vaccin
mice
determin
level
lung
viru
load
morbid
postchalleng
howev
rsvg
vlp
found
greater
efficaci
rsvf
vlp
anoth
rsv
vaccin
candid
manufactur
novavax
inc
rockvil
md
repres
nanoparticl
compos
near
fulllength
rsv
f
protein
express
insect
cell
assembl
trimer
phase
blind
random
placebocontrol
clinic
trial
rsvf
vlp
vaccin
candid
gener
strong
dosedepend
rsvfspecif
plaquereduct
neutral
antibodi
respons
augment
presenc
adjuv
aluminum
phosphat
insect
cellproduc
vlpbase
vaccin
develop
studi
underway
target
number
pathogen
includ
dengu
viru
rift
valley
viru
ebola
viru
sar
cov
human
parvoviru
polioviru
enteroviru
herp
simplex
viru
polyoma
virus
approach
also
appli
develop
veterinari
vaccin
varieti
potenti
veterinari
vaccin
base
vlp
produc
insect
cell
includ
bluetongu
viru
chicken
anemia
viru
goos
hemorrhag
polyoma
viru
infecti
bursal
diseas
viru
ndv
porcin
mink
canin
parvovirus
porcin
circoviru
rabbit
hemorrhag
diseas
viru
swine
vesicular
stomat
viru
vlp
vaccin
candid
includ
bluetongu
viru
bovin
papillomaviru
type
chicken
anemia
viru
infecti
bursal
diseas
viru
porcin
mink
canin
parvovirus
porcin
encephalomyocard
viru
evalu
natur
target
host
found
protect
live
viru
challeng
approv
veterinari
vlpbase
vaccin
porcili
pcv
intervet
intern
bv
netherland
current
merck
anim
health
compos
porcin
circoviru
type
antigen
produc
baculovirusinfect
cell
shown
protect
pig
porcin
circoviru
type
infect
vaccin
market
sinc
abil
perform
complex
mammaliantyp
ptm
recombin
protein
main
advantag
avian
mammalian
cell
express
system
high
product
cost
potenti
safeti
concern
remain
challeng
similar
recombin
express
system
mammalian
cell
increasingli
use
produc
vlpbase
vaccin
candid
array
pathogen
mention
earlier
section
hbsag
vlp
success
produc
mammalian
cell
chines
hamster
ovari
cho
cell
line
mammalian
cellproduc
hbsag
vlp
similar
plasmaderiv
hbsag
vlp
composit
protein
glycosyl
yeastproduc
vlp
lipid
content
larger
size
consist
greater
number
monom
compar
yeastderiv
vlp
contribut
higher
immunogen
mammalianorigin
vlp
addit
contrast
hbsag
vlp
yeast
origin
cho
cellproduc
hbsag
vlp
shown
undergo
intracellular
assembl
packag
er
tubular
structur
addit
singleantigen
vlp
contain
hbsag
protein
multiantigen
vlp
vaccin
contain
either
hbsag
pre
domain
hbsag
l
protein
pre
pre
domain
produc
cho
cell
demonstr
safe
immunogen
neonat
due
presenc
broaderrang
hbsag
epitop
vaccin
believ
immunogen
fast
act
provid
better
protect
compar
vlp
vaccin
contain
hbsag
protein
alon
two
vaccin
genhevac
b
scibvac
formerli
biohepb
tm
develop
franc
israel
respect
market
tabl
hepacar
anoth
multiantigen
hbsag
vlp
vaccin
indic
immun
nonimmun
adult
year
age
develop
medeva
pharma
ltd
unit
kingdom
receiv
market
author
europ
subsequ
voluntarili
withdrawn
compani
commerci
reason
anoth
target
mammalian
cellproduc
vlp
vaccin
denv
caus
agent
dengu
fever
product
denv
vlp
resembl
denv
virion
size
morpholog
achiev
coexpress
prm
e
structur
protein
cho
mammalian
cell
line
includ
incorpor
er
retent
signal
stemtransmembran
region
e
protein
howev
immunogen
protect
efficaci
vlp
assess
use
dna
vaccin
encod
protein
similar
vaccin
approach
appli
toward
flavivirus
includ
murray
valley
enceph
viru
japanes
enceph
viru
west
nile
viru
subvir
particl
compos
prm
e
protein
murray
valley
enceph
viru
abl
protect
vaccin
mice
lethal
challeng
virul
wildtyp
viru
strain
protect
correl
develop
neutral
antibodi
contrast
cellassoci
recombin
e
protein
neither
protect
mice
induc
neutral
antibodi
recent
studi
vlp
four
differ
denv
serotyp
evalu
vaccin
candid
mice
monoval
vlp
serotyp
stimul
specif
igg
respons
potent
neutral
antibodi
homotyp
viru
tetraval
vlp
induc
specif
igg
neutral
antibodi
four
serotyp
denv
addit
monoval
tetraval
vlp
gener
virusspecif
ctl
respons
challeng
diseas
agent
mammalian
cell
express
system
appli
vaccin
candid
product
includ
ebola
marburg
filovirus
infect
result
manifest
deadli
rapidli
progress
hemorrhag
fever
approv
vaccin
avail
vlp
target
virus
gener
use
cdnatransfect
human
embryon
kidney
hek
cell
express
system
type
vlp
compris
viral
matrix
protein
envelop
glycoprotein
close
resembl
distinct
filament
parent
viral
particl
shown
em
vlp
target
either
ebola
marburg
fever
highli
immunogen
protect
viral
challeng
anim
model
ebola
vlp
shown
activ
mous
dc
vitro
cell
well
b
cell
vivo
vaccin
mice
vlp
target
ebola
fever
elicit
high
level
ebola
virusspecif
antibodi
includ
neutral
antibodi
confer
complet
protect
lethal
ebola
viru
challeng
protect
depend
activ
natur
killer
cell
requir
humor
ctl
ebola
virusspecif
respons
vlp
target
marburg
fever
induc
celldepend
prolif
respons
vitro
upon
reexposur
homolog
antigen
vaccin
guinea
pig
elicit
high
titer
marburg
virusspecif
antibodi
includ
neutral
antibodi
confer
complet
protect
lethal
marburg
viru
challeng
taken
togeth
strong
immunogen
protect
capac
ebola
marburg
vlp
make
promis
vaccin
candid
deadli
filoviru
infect
hantaan
viru
etiolog
agent
hemorrhag
fever
renal
syndrom
anoth
pathogen
requir
develop
medic
countermeasur
includ
vaccin
point
vlp
contain
np
two
envelop
glycoprotein
hantaan
viru
produc
recombin
vaccinia
virusinfect
vero
babi
hamster
kidney
bhk
cho
cell
result
vlp
demonstr
immunogen
mous
model
induc
antibodi
respons
hantaan
viru
np
glycoprotein
cellular
respons
np
follow
im
sc
administr
chikungunya
viru
transmit
mosquito
caus
tropic
infect
similar
dengu
fever
specif
treatment
diseas
vaccin
licens
chikungunya
vlp
form
c
protein
produc
hek
cell
exhibit
morpholog
similar
sindbi
viru
follow
im
vaccin
vlp
elicit
high
titer
neutral
antibodi
react
homolog
heterolog
strain
chikungunya
viru
mice
rhesu
macaqu
furthermor
vaccin
monkey
protect
viremia
inflamm
associ
highdos
viral
challeng
protect
antibodymedi
shown
passiv
transfer
purifi
total
igg
protect
monkey
immunodefici
mice
follow
subleth
viral
challeng
ndv
econom
signific
poultri
pathogen
current
avail
live
vaccin
insuffici
safe
protect
explor
potenti
nd
vlp
nd
vaccin
produc
avian
fibroblast
cell
line
transfect
cdna
encod
hn
f
np
protein
ndv
strain
av
protein
concentr
ratio
purifi
vlp
compar
uvinactiv
ndv
glycoprotein
incorpor
vlp
exhibit
intact
function
activ
adjuvantfre
administr
nd
vlp
elicit
equal
greater
level
ndvspecif
neutral
serum
antibodi
cell
immun
mice
compar
inactiv
ndv
vlp
also
form
hn
f
protein
ndv
strain
incorpor
suggest
broadspectrum
ndv
vaccin
potenti
nd
vlp
includ
exot
ndv
strain
nipah
viru
niv
determin
caus
zoonot
diseas
outbreak
south
asia
associ
highli
lethal
febril
enceph
human
predominantli
respiratori
diseas
pig
potenti
agent
agroterror
develop
niv
vaccin
chimer
ndvbase
vlp
construct
niv
g
protein
fuse
transmembran
tm
cytoplasm
ct
domain
ndv
hn
protein
produc
use
cdnatransfect
avian
fibroblast
cell
niv
vlp
form
niv
g
f
protein
also
produc
substanti
quantiti
cdnatransfect
hek
cell
assembl
vlp
resembl
parent
niv
virion
size
nm
morpholog
surfac
composit
shown
transmiss
em
cryoem
niv
vlp
fusogen
induc
syncytia
format
activ
innat
immun
defens
mechan
gene
immun
vlp
without
adjuv
elicit
neutral
antibodi
respons
mice
indic
vaccin
potenti
approach
similar
use
ndvbase
niv
vlp
employ
produc
recombin
rsv
vlp
vaccin
candid
specif
rsv
g
f
protein
fuse
tm
ct
domain
ndv
hn
f
protein
respect
chimer
vlp
produc
cdnatransfect
cell
result
ndvrsv
chimer
vlp
shown
stimul
antirsv
antibodi
respons
mice
confer
protect
rsv
challeng
altern
rsv
vaccin
candid
produc
express
fulllength
rsv
f
g
glycoprotein
live
recombin
sendai
viru
sv
vaccinia
virusinfect
mammalian
cell
follow
propag
recombin
viru
egg
svrsvg
vlp
elicit
rsvspecif
antibodi
confer
protect
rsv
challeng
follow
inocul
cotton
rat
prepar
recombin
sv
vaccin
express
rsv
f
protein
also
report
chimer
particl
elicit
rsvspecif
neutral
antibodi
cell
respons
cotton
rat
follow
immun
furthermor
vaccin
also
confer
protect
challeng
rsv
even
mismatch
origin
sequenc
differ
subtyp
similarli
sv
platform
use
produc
vaccin
human
parainfluenza
virus
hpiv
display
f
protein
hemagglutininneuraminidas
recombin
sv
particl
gener
longlast
bind
neutral
antibodi
respons
well
cell
respons
protect
hpiv
challeng
two
group
construct
rsv
vaccin
display
solubl
core
domain
rsv
g
glycoprotein
amino
acid
recombin
replicationdefici
adenoviru
adv
particl
rsv
g
f
fulllength
protein
defect
nonpropag
venezuelan
equin
enceph
viru
veev
replicon
particl
produc
result
chimer
particl
mammalian
cell
singl
immun
either
chimer
particl
induc
strong
serum
igg
mucos
iga
respons
mice
cotton
rat
provid
longterm
protect
rsv
challeng
veevbas
rsv
vaccin
also
induc
cell
respons
protect
display
rsvf
emerg
strain
influenza
viru
respons
season
epidem
rare
pandem
underscor
import
rapid
largescal
develop
vaccin
novel
viru
strain
influenza
vlp
gener
mammalian
system
coexpress
ha
na
protein
without
protein
plasmidtransfect
hek
cell
ha
na
protein
transfect
vero
cell
influenza
vlp
produc
vero
cell
resembl
parent
influenza
virion
particl
size
morpholog
demonstr
transmiss
em
dynam
light
scatter
ha
glycosyl
pattern
reveal
ndeglycosyl
assay
vaccin
mice
vlp
gener
antibodi
hai
antibodi
confer
full
protect
lethal
challeng
homolog
viru
addit
singl
pathogen
target
influenza
vlp
chimer
vlp
produc
via
pseudotyp
influenza
viral
protein
onto
retrovir
gag
vlp
thu
pseudotyp
chimer
mlv
gag
particl
carri
ha
mostli
cleav
ha
ha
product
na
highli
pathogen
avian
influenza
strain
produc
transient
cotransfect
hek
cell
mice
vaccin
vlp
develop
rapid
robust
subtypespecif
neutral
antibodi
respons
even
singl
immun
crossreact
determin
immun
serum
neutral
vlp
transduct
titer
howev
neutral
live
virus
use
hai
assay
yet
report
last
two
decad
plant
demonstr
great
potenti
product
recombin
protein
industri
pharmaceut
purpos
includ
vaccin
develop
product
platform
plant
express
system
rapid
highli
scalabl
costeffect
free
mammalian
pathogen
furthermor
protein
structur
assembl
ptm
plant
similar
mammalian
cell
express
recombin
protein
plant
achiev
either
via
stabl
introduct
transgen
nuclear
plastid
genom
mean
transient
transform
use
plant
viral
vector
similar
mammalian
insect
yeast
cell
plant
use
produc
nonenvelop
envelop
vlp
envelop
nonenvelop
plantproduc
vlp
vaccin
candid
produc
larg
scale
current
good
manufactur
practic
cgmp
condit
progress
clinic
develop
vlp
form
gag
protein
produc
plant
via
stabl
transient
transform
biolisticmedi
transform
nicotiana
tabacum
dna
vector
contain
sequenc
result
highlevel
express
polyprotein
transgen
chloroplast
format
spheric
gag
vlp
vlp
nm
diamet
also
observ
follow
highlevel
transient
express
nicotiana
benthamiana
agroinfiltr
use
tmvbase
vector
studi
gag
vlp
morpholog
similar
vlp
produc
insect
cell
furthermor
transgen
chloroplastderiv
gag
vlp
induc
gagspecif
antibodi
respons
mice
three
ip
inject
compar
elicit
dose
insect
cellproduc
gag
vlp
addit
vlp
assembl
hiv
gag
protein
bival
hbvhiv
vaccin
candid
also
engin
hbsag
vlp
display
immunogen
epitop
hiv
envgag
produc
transgen
tomato
hbsag
vlp
carri
hiv
polenvgag
epitop
produc
transgen
n
tabacum
arabidopsi
thaliana
type
chimer
hbvhiv
vlp
produc
low
level
follow
oral
administr
mice
envgag
epitopecontain
vlp
gener
weak
humor
immun
respons
polenvgag
epitopecontain
vlp
induc
cellular
immun
respons
toler
transient
transform
plant
hiv
immunogen
epitop
express
form
fusion
plant
viru
cp
form
nonenvelop
chimer
vlp
exampl
acid
long
peptid
envelop
protein
strain
iiib
amino
acid
known
induc
crossreact
neutral
antibodi
hivinfect
human
insert
loop
protein
cpmv
result
chimer
vlp
demonstr
induc
neutral
serum
antibodi
mice
follow
sc
immun
presenc
alum
adjuv
addit
mice
vaccin
vlp
presenc
cholera
toxin
mucos
adjuv
via
oral
administr
develop
mucos
system
iga
antibodi
respons
anoth
studi
highli
conserv
eldkwa
epitop
genet
fuse
nterminu
pvx
cp
purifi
chimer
vlp
induc
high
titer
neutral
igg
iga
antibodi
mice
follow
ip
deliveri
notabl
vlp
also
shown
stimul
human
peripher
blood
lymphocyt
hupbl
produc
antibodi
epitop
shown
immun
hupblreconstitut
sever
combin
immunodefici
mice
vlppuls
autolog
dc
sera
normal
human
mice
possess
neutral
activ
anoth
studi
loop
protein
fuse
almv
cp
clone
tmvbase
vector
inocul
n
benthamiana
infecti
vitro
synthes
transcript
result
accumul
chimer
viral
particl
shown
elicit
antigenspecif
virusneutr
antibodi
ip
immun
mice
similarli
chimer
almv
cp
vlp
engin
express
acid
peptid
repres
amino
acid
rsv
g
protein
vmrrsv
plant
chimer
particl
gener
strong
humor
cellular
immun
respons
vitro
use
puls
human
dc
well
vivo
introduc
nonhuman
primat
earlier
studi
almv
vlp
display
peptid
elicit
potent
antibodi
respons
protect
viral
challeng
infect
mice
librari
acid
long
peptid
rsv
f
protein
fuse
nterminu
almv
cp
acid
overlap
span
whole
protein
screen
potenti
b
cell
cell
epitop
use
dc
stimul
assay
human
peripher
blood
mononuclear
cell
pbmc
five
peptid
found
elicit
secret
cell
stimul
one
recogn
five
pbmc
donor
use
studi
epitopebas
vaccin
develop
approach
also
employ
anthrax
fuse
target
peptid
cp
plant
virus
one
studi
acid
long
peptid
protect
antigen
pa
b
anthraci
fuse
surfac
loop
larg
subunit
cpmv
cp
propag
cowpea
result
chimer
cpmv
cp
vlp
display
copi
anthrax
peptid
gener
multigram
quantiti
anoth
group
fuse
small
loop
acid
long
epitop
domain
pa
ntermin
region
almv
cp
infecti
transcript
recombin
almv
use
inocul
transgen
n
tabacum
express
almv
replicas
gene
chimer
almv
particl
accumul
plant
larg
quantiti
extend
time
period
ip
administr
almvanthrax
vlp
elicit
detect
anthraxspecif
antibodi
respons
two
five
immun
mice
compar
mice
immun
control
recombin
almv
purifi
pa
chimer
almv
particl
platform
also
use
develop
plagu
vaccin
candid
librari
acid
long
peptid
yersinia
pesti
protein
fuse
nterminu
almv
cp
acid
overlap
span
whole
protein
screen
potenti
b
cell
cell
epitop
use
dc
stimul
assay
human
pbmc
ten
test
pesti
construct
stimul
cell
three
recogn
pbmc
seven
ten
donor
use
studi
anoth
studi
integr
loop
hbcag
result
chimer
protein
shown
immunogen
mice
howev
vlp
format
observ
fusion
chimer
peptid
contain
b
cell
epitop
gp
cell
epitop
np
rabi
viru
cp
almv
introduct
sequenc
n
benthamiana
spinach
leav
use
tmvbase
vector
result
replic
recombin
almv
transient
express
peptid
chimer
viral
particl
chimer
vlp
display
rabi
peptid
shown
accumul
infect
leav
purifi
vlp
elicit
rabiesspecif
neutral
antibodi
respons
mice
follow
ip
immun
notabl
ingest
raw
leaf
materi
contain
vlp
also
induc
antirabi
antibodi
respons
human
volunt
previous
immun
convent
rabi
vaccin
indic
potenti
supplementari
oral
booster
rabi
vaccin
tabl
new
vlp
vaccin
candid
rabi
produc
agroinfiltr
n
benthamiana
plant
develop
medicago
inc
quebec
qc
canada
preclin
studi
two
dose
vaccin
demonstr
induc
protect
level
neutral
antibodi
mice
sever
studi
attempt
made
develop
malaria
vaccin
use
chimer
vlp
base
plant
virus
tmv
cpmv
select
malari
b
cell
epitop
fuse
either
surfac
loop
region
cterminu
tmv
cp
use
leaki
stop
signal
mechan
coassembl
vlp
cpmalaria
epitop
fusion
wildtyp
cp
tobacco
plant
demonstr
anoth
studi
malaria
merozoit
peptid
display
small
cp
cpmv
chimer
viral
particl
shown
induc
peptidespecif
serum
antibodi
rabbit
cpmv
also
use
engin
produc
human
rhinoviru
vaccin
candid
insert
acid
long
epitop
loop
cpmv
protein
maintain
epitop
close
nativelik
conform
immunogen
result
product
chimer
vlp
cowpea
inocul
infecti
vitro
rna
transcript
rabbit
immun
im
sc
two
dose
purifi
chimer
vlp
presenc
freund
adjuv
gener
serum
antibodi
chimer
nonrepl
cpmv
particl
express
peptid
deriv
fibronectinbind
protein
b
fnbp
motif
first
amino
acid
domain
staphylococcu
aureu
fuse
loop
protein
shown
work
mucos
vaccin
aureu
mice
vaccin
vlp
without
adjuv
gener
fnbpspecif
system
mucos
antibodi
respons
bia
toward
type
includ
serum
igg
mucos
iga
igg
even
distant
mucos
site
sera
immun
mice
complet
inhibit
bind
human
fibronectin
aureu
fnbp
contrast
oral
immun
induc
lower
antibodi
titer
serum
intestin
iga
subsequ
studi
immun
vlp
protect
rat
develop
aureusassoci
endocard
p
opson
aureu
antibodi
rais
chimer
cpmv
vlp
stimul
neutrophil
activ
macrophag
phagocytosi
vitro
furthermor
intraven
passiv
transfer
antibodi
protect
recipi
mice
bacteremiarel
weight
loss
surfaceexpos
linear
b
cell
epitop
peptid
outer
membran
om
protein
f
pseudomona
aeruginosa
express
tandem
protein
f
peptid
two
cp
cpmv
small
larg
l
chimer
vlp
express
peptid
cp
l
cp
elicit
peptidespecif
antibodi
immun
mice
abl
induc
p
aeruginosaspecif
opson
confer
protect
challeng
two
differ
immunotyp
p
aeruginosa
mous
model
chronic
pulmonari
infect
indic
potenti
develop
protect
vaccin
bacterium
cpmvbase
vlp
also
success
use
produc
vaccin
mink
enter
viru
canin
parvoviru
felin
panleukopenia
viru
chimer
cpmv
vlp
engin
display
epitop
share
mink
enter
viru
canin
parvoviru
felin
panleukopenia
viru
produc
blackey
bean
vigna
unguiculata
sc
vaccin
vlp
found
protect
mink
clinic
diseas
viru
shed
challeng
virul
mink
enter
viru
dog
lethal
challeng
canin
parvoviru
anoth
studi
acid
long
peptid
canin
parvoviru
fuse
small
larg
subunit
cp
display
chimer
cpmv
particl
mice
vaccin
sc
chimer
vlp
develop
peptidespecif
antibodi
respons
immun
respons
markedli
bias
determin
predominantli
isotyp
secret
releas
antigenstimul
lymphocyt
vitro
notabl
sc
vaccin
induc
serum
neutral
antibodi
peptidespecif
mucos
iga
antibodi
intestin
bronchial
lavag
fluid
combin
system
mucos
rout
prime
boost
vaccin
alter
bia
immun
respons
result
optim
serum
intestin
antibodi
product
sever
public
report
product
hpv
vlp
plant
use
transgen
transplastom
transient
express
system
stabli
express
n
tabacum
cv
xanthi
demonstr
assembl
capsom
vlp
retain
neutral
conform
epitop
rabbit
immun
plantproduc
particl
develop
weak
immun
respons
protein
without
ctermin
nuclear
local
signal
sequenc
enhanc
mrna
stabil
protein
accumul
produc
high
level
transgen
thaliana
n
tabacum
cv
xanthi
immun
rabbit
transgen
plant
extract
induc
low
titer
serum
antibodi
neither
react
nativ
vlp
neutral
infecti
pseudovirion
express
plant
codonoptim
protein
delet
ctermin
nuclear
local
signal
sequenc
transgen
potato
result
format
abund
diamet
spheric
vlp
resembl
authent
hpv
virion
shown
em
analysi
tuber
extract
feed
mice
transgen
potato
tuber
elicit
antihpv
antibodi
respons
markedli
enhanc
follow
oral
boost
purifi
vlp
produc
insect
cell
anoth
studi
protein
express
low
modest
level
transgen
tobacco
potato
selfassembl
vlp
small
portion
capsom
transgen
tobacco
confirm
em
sucros
gradient
analys
immunogen
vlp
compar
hpv
vlp
produc
insect
cell
mice
fed
tuber
transgen
potato
three
mice
develop
weak
antibodi
respons
respons
significantli
enhanc
follow
ip
oral
boost
subimmunogen
dose
purifi
insect
cellderiv
vlp
indic
effici
prime
plantproduc
vlp
contrast
vlp
format
transgen
potato
tobacco
modifi
protein
selfassembl
capsom
transplastom
tobacco
transient
express
vlp
n
benthamiana
plant
achiev
use
tmv
bean
yellow
dwarf
viru
bydv
cpmv
vector
inocul
plant
infecti
vitro
rna
transcript
tmvbase
vector
shown
result
assembl
capsom
vlp
retain
neutral
conform
epitop
elicit
weak
immun
respons
rabbit
shuttl
vector
combin
viral
replicon
bydv
singlestrand
dna
geminiviru
ti
plasmid
tumefacien
use
rapidli
produc
protein
cpmv
vector
system
also
employ
produc
chimer
vlp
capsom
bear
influenza
epitop
repres
first
record
success
express
chimer
particl
carri
epitop
heterolog
viru
plant
mammalian
insect
cell
plant
use
produc
vlp
compos
nv
cp
nv
cp
vlp
shown
highli
immunogen
nv
cp
vlp
express
potato
tuber
icosahedr
particl
similar
produc
insect
cell
consist
nv
virion
size
predomin
vlp
form
tomato
fruit
small
particl
also
observ
insect
cellderiv
nv
cp
prepar
feed
raw
transgen
potato
tuber
lyophil
powder
transgen
tomato
fruit
contain
properli
assembl
nv
cp
vlp
elicit
potent
serum
igg
intestin
iga
antibodi
respons
mice
feed
uncook
transgen
potato
tuber
result
posit
safeti
immunogen
data
human
volunt
induc
serum
igg
iga
respons
tabl
nv
cp
vlp
also
transient
express
n
benthamiana
use
either
tmvbase
magnicon
deconstruct
vector
system
bydvbas
shuttl
vector
oral
immun
mice
partial
purifi
nv
cp
vlp
prepar
use
magnicon
vector
shown
induc
strong
system
mucos
virusspecif
antibodi
respons
recent
report
demonstr
success
product
vlp
vaccin
candid
cgmp
condit
test
phase
clinic
trial
vlp
compos
rv
structur
protein
produc
transgen
tomato
tobacco
shown
morpholog
similar
nativ
rv
particl
rate
vlp
assembl
tomato
howev
low
plant
extract
contain
vlp
adjuv
gener
rvspecif
system
mucos
antibodi
respons
mice
deliv
oral
system
respons
administ
ip
protect
rv
infect
examin
studi
vlp
form
hbsag
hbcag
produc
transgen
transient
transform
plant
mice
fed
hbsag
vlpcontain
transgen
tobacco
potato
materi
develop
cellular
humor
immun
respons
feed
hbsagexpress
transgen
lettuc
potato
elicit
antihbsag
serum
antibodi
human
volunt
receiv
two
dose
transgen
plant
materi
previous
vaccin
licens
hbv
vaccin
tabl
studi
explor
assembl
immunogen
hbsag
polypeptid
express
plant
transgen
tobacco
soybean
cell
suspens
well
potato
leav
tuber
polypeptid
found
selfassembl
tubular
membran
complex
deriv
er
similar
hbsag
particl
assembl
cho
cell
display
extens
disulfidebond
crosslink
immunogen
epitop
complex
size
distribut
particl
differenti
vlp
prepar
observ
commerci
hbsag
vlp
vaccin
deriv
recombin
h
polymorpha
furthermor
hbsag
polypeptid
contain
addit
acid
long
pre
region
nterminu
protein
express
transient
stabli
transform
n
benthamiana
shown
form
vlp
ip
administr
purifi
vlp
elicit
stronger
serum
antibodi
respons
hbsag
mice
compar
protein
recombin
hbcag
express
transgen
tobacco
leav
shown
assembl
spheric
particl
nm
diamet
maintain
two
antigen
determin
hbcag
transient
express
hbcag
n
benthamiana
achiev
use
pvx
cpmvbase
vector
although
vector
system
allow
correct
assembl
hbcag
vlp
confirm
immunoem
express
level
low
wildtyp
plant
viru
particl
coproduc
contrast
use
magnicon
vector
system
gene
optim
plant
express
dramat
increas
level
hbcag
vlp
product
achiev
total
solubl
protein
fresh
weight
nm
particl
observ
similar
hbcag
vlp
produc
e
coli
partial
purifi
hbcag
vlp
immunogen
mice
administ
ip
imject
alum
adjuv
serum
igg
oral
without
adjuv
serum
igg
mucos
iga
suggest
strong
potenti
hbcag
vlp
hbv
vaccin
also
foreign
epitop
present
system
mucos
deliveri
inde
hbcag
fuse
neutral
epitop
protein
form
chimer
vlp
bydvbas
shuttl
vector
also
use
rapidli
produc
hbcag
vlp
n
benthamiana
recent
envelop
vlp
vaccin
candid
influenza
transient
produc
plant
use
plant
viral
binari
vector
system
pvxbase
chimer
viru
particl
display
b
restrict
epitop
influenza
np
construct
produc
n
benthamiana
shown
stimul
mhc
class
irestrict
peptidespecif
cell
mice
administ
without
adjuv
transient
express
ha
anew
influenza
viru
strain
perform
medicago
inc
use
binari
vector
agroinfiltr
n
benthamiana
ha
assembl
vlp
morpholog
similar
produc
mammalian
insect
cell
confirm
em
notabl
vlpassoci
lipid
shown
deriv
plant
cell
plasma
membran
wherea
bud
plasma
membran
demonstr
plant
virus
im
immun
two
low
dose
adjuv
induc
hai
antibodi
respons
mice
stronger
achiev
solubl
ha
antigen
also
induc
crossreact
hai
antibodi
ferret
confer
complet
protect
lethal
challeng
heterolog
influenza
viru
strain
mice
ferret
evalu
adjuv
administ
im
two
dose
healthi
adult
phase
phase
clinic
trial
demonstr
good
safeti
profil
strong
immunogen
clear
dose
respons
tabl
vaccin
candid
base
swine
influenza
viru
strain
also
test
phase
random
placebocontrol
clinic
trial
involv
healthi
adult
receiv
singl
inject
nonadjuv
vlp
vaccin
dose
test
vaccin
shown
safe
well
toler
strong
immunogen
confirm
hai
singl
radial
hemolysi
microneutr
antibodi
assay
tabl
insect
cellproduc
vlp
plantderiv
influenza
vlp
potenti
valu
veterinari
vaccin
swine
bird
respect
footandmouth
diseas
sever
viral
infect
affect
farm
anim
complet
open
read
frame
orf
code
major
immunogen
protein
footandmouth
diseas
viru
fmdv
express
surfac
recombin
tmv
particl
via
inocul
vitro
rna
transcript
n
benthamiana
ip
immun
mice
foliar
extract
infect
leav
elicit
antibodi
respons
confer
protect
virul
fmdv
challeng
two
immunogen
domin
epitop
fmdv
serotyp
amino
acid
long
fuse
tmv
cp
orf
amino
acid
residu
express
tobacco
result
chimer
particl
abl
system
infect
tobacco
produc
larg
quantiti
stabl
progeni
viral
particl
assembl
modifi
cp
subunit
vlp
confer
full
protect
guinea
pig
parenter
immun
partial
protect
oral
administr
serum
immun
anim
contain
virusneutr
antibodi
protect
also
demonstr
swine
model
similarli
chimer
bamboo
mosaic
viru
bamv
base
vlp
express
epitop
fmdv
produc
chenopodium
quinoa
immunoem
confirm
presenc
bamv
cp
fmdv
surfac
particl
purifi
vlp
induc
cellular
humor
immun
respons
pig
protect
anim
fmdv
challeng
recent
tnva
c
use
vector
express
peptid
fmdv
serotyp
clone
downstream
cp
orf
chenopodium
amaranticolor
via
inocul
vitro
transcript
im
administr
purifi
chimer
vlp
elicit
strong
system
antibodi
respons
wherea
immun
induc
system
mucos
antibodi
respons
use
anoth
plant
viru
cucumb
mosaic
viru
cmv
hcv
vaccin
candid
engin
chimer
cmv
cpbase
vlp
display
acid
long
synthet
peptid
deriv
hypervari
region
sequenc
hcv
envelop
protein
socal
mimotop
fuse
cmv
cp
vlp
demonstr
stabil
vitro
simul
gastrointestin
condit
rabbit
fed
lettuc
develop
antibodi
respons
suggest
efficaci
edibl
cmv
vlpbase
hcv
vaccin
pvxcmv
cp
transient
express
system
use
produc
vlp
present
epitop
ndv
n
benthamiana
use
vitro
transcript
inocul
approach
system
cmv
cp
express
control
pvx
subgenom
promot
selfassembl
cmv
vlp
encapsid
subgenom
rna
encod
cmv
cp
pvx
rna
downstream
hybrid
viru
two
short
neutral
ndv
epitop
chosen
fuse
loop
motif
cmv
cp
acid
epitop
ndv
f
protein
amino
acid
acid
epitop
ndv
hn
protein
amino
acid
epitop
fuse
tandem
chimer
vlp
stabli
express
plant
correct
present
fold
epitop
confirm
use
ndvspecif
antisera
furthermor
transmiss
em
sucros
gradientpurifi
vlp
prepar
show
morpholog
ident
wildtyp
cmv
particl
immun
ndv
epitopecarri
cmv
cp
vlp
induc
antigenspecif
antibodi
chicken
addit
target
infecti
diseas
vlp
produc
plant
use
platform
develop
vaccin
selfantigen
involv
pathogenesi
neurodegen
diseas
thu
fusion
fragment
amyloid
protein
peptid
cmv
cp
posit
result
complet
peptid
decor
chimer
viru
particl
shown
immunoem
use
either
polyclon
antibodi
result
suggest
potenti
chimer
vlp
vaccin
candid
alzheim
diseas
vlp
also
made
vitro
cellfre
condit
assembl
virosom
use
membranelik
structur
similar
membran
envelop
vlp
use
polypeptid
scaffold
give
nanovlp
similar
nonenvelop
vlp
nanovlp
one
latest
develop
field
test
preclin
set
approach
use
natur
properti
amino
acid
polypeptid
selfassembl
allow
insert
immunogen
epitop
although
earli
stage
develop
approach
show
promis
recombin
vaccin
design
develop
virosom
hand
use
present
target
antigen
number
pathogen
enter
clinic
develop
see
section
virosom
essenti
repres
envelop
vlp
assembl
vitro
rather
insid
host
cell
product
virosom
purifi
inactiv
parent
viru
undergo
deterg
dissoci
separ
envelop
fraction
contain
lipid
membraneassoci
viral
protein
core
complex
contain
intern
protein
genet
materi
upon
remov
deterg
envelop
fraction
compon
assembl
empti
virosom
particl
depend
desir
type
immun
respons
induc
virosom
vaccin
recombin
synthet
antigen
either
display
virosom
surfac
integr
anchorag
lipid
bilay
crosslinkag
membraneassoci
viral
protein
via
lipid
anchor
absorb
bilay
surfac
incorpor
lumen
stimul
antibodi
product
ctl
respons
respect
virosom
carri
ha
na
influenza
viru
produc
evalu
vaccin
candid
earli
lead
commerci
two
licens
human
vaccin
crucel
epax
hepat
inflex
v
season
influenza
sever
influenza
virosomebas
vaccin
produc
pevion
biotech
ag
bern
switzerland
also
differ
stage
clinic
develop
tabl
therapeut
virosom
hcv
vaccin
candid
develop
clear
chronic
hepat
c
infect
vaccin
engin
encapsul
two
viral
peptid
ctl
epitop
virosom
display
one
viral
peptid
cell
epitop
virosom
surfac
thu
intend
induc
cellular
humor
immun
respons
phase
studi
vaccin
well
toler
level
cell
respons
satisfactori
bival
virosom
malaria
vaccin
display
two
synthet
peptid
two
p
falciparum
protein
csp
apic
membran
antigen
design
induc
protect
antibodi
respons
sporozoit
merozoit
test
four
phase
clinic
trial
demonstr
safeti
immunogen
abil
produc
longlast
sporozoiteinhibitori
antibodi
titer
exampl
vaccin
candida
albican
engin
link
recombin
truncat
form
protein
virul
factor
fungu
virosom
induc
protect
mucos
antibodi
demonstr
safe
highli
immunogen
ongo
phase
clinic
trial
similarli
breast
cancer
vaccin
design
display
three
synthet
peptid
protein
virosom
phase
clinic
trial
conduct
patient
metastat
breast
cancer
vaccin
shown
safe
elicit
high
antibodi
titer
selfpeptid
even
low
dose
induc
antibodi
recogn
synthet
peptid
also
fulllength
protein
pevion
monoval
virosom
hiv
vaccin
candid
display
recombin
peptid
influenza
virosom
deliv
via
combin
im
rout
shown
protect
nonhuman
primat
vagin
shiv
challeng
protect
mediat
vagin
transcytosisblock
vagin
iga
antibodi
vagin
igg
antibodi
neutral
andor
antibodydepend
cellular
cytotox
activ
vaccin
current
test
safeti
prophylact
efficaci
healthi
femal
volunt
phase
clinic
trial
tabl
addit
virosom
vaccin
licens
clinic
develop
virosom
vaccin
candid
undergo
preclin
evalu
includ
rsv
virosom
vaccin
either
display
recombin
rsvf
protein
influenza
virosom
repres
reconstruct
rsv
virosom
carri
tolllik
receptorbind
immunomodul
lipid
adjuv
envelop
proofofconcept
anim
studi
rsv
vaccin
elicit
humor
cellmedi
immun
respons
type
confer
protect
live
rsv
challeng
base
result
pevion
rsv
vaccin
candid
expect
enter
combin
clinic
phase
clinic
studi
healthi
volunt
includ
control
viru
challeng
last
four
decad
signific
increas
develop
recombin
suv
use
heterolog
express
system
antigen
mani
viral
bacteri
parasit
fungal
pathogen
test
effect
safe
vaccin
develop
number
case
specif
vaccin
antigen
produc
use
differ
express
system
perform
compar
well
licens
recombin
vaccin
suggest
critic
import
design
represent
specif
antigen
abil
gener
protect
immun
respons
although
mani
antigen
produc
evalu
compon
candid
suv
reach
market
today
recombin
suv
market
base
vlp
suv
approach
market
base
vlp
protein
scienc
influenza
vaccin
howev
even
case
vaccin
consist
trimer
higherord
aggreg
ha
gain
knowledg
pathogen
human
immun
system
hostpathogen
interact
mechan
enhanc
targetspecif
immun
respons
anticip
broader
rang
suv
develop
potenti
includ
nonvlpbas
exampl
date
howev
vlpbase
suv
appear
superior
elicit
targetspecif
protect
respons
human
although
underli
mechan
protect
immun
respons
elicit
vlpbase
suv
fulli
understood
critic
import
vlp
greater
structur
complex
emphas
mani
studi
vlp
design
allow
produc
multicompon
vaccin
structur
resembl
human
anim
pathogen
thu
recogn
human
immun
system
similar
manner
pathogen
protein
compon
present
vlp
structur
similarli
present
pathogen
reproduc
effect
use
nonvlp
approach
current
feasibl
particul
structur
multival
epitop
organ
reason
stronger
immunogen
protect
efficaci
vlp
compar
nonassembl
suv
purif
procedur
result
highli
pure
solubl
protein
vlp
produc
differ
express
system
often
contamin
residu
host
cell
compon
lipid
nucleic
acid
protein
may
stimul
innat
immun
augment
adapt
immun
respons
exampl
yeast
cell
membran
compon
contamin
prepar
yeastderiv
vlp
shown
contribut
dc
activ
effect
partial
mediat
signal
tolllik
receptor
similarli
compon
insect
cell
recombin
baculovirus
induc
activ
dc
antigen
present
cell
promot
strong
typebias
immun
respons
accord
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
regulatori
guidelin
howev
host
cell
contamin
affect
immun
system
repres
major
safeti
concern
may
signific
impact
vaccin
develop
path
base
approach
lesson
learn
develop
use
current
vlp
well
full
pathogenbas
vaccin
would
highli
valubl
continu
use
approach
success
product
develop
addit
vlp
offer
econom
approach
produc
suv
sever
recombin
system
success
use
vlp
product
promis
efficaci
report
mani
vlp
vaccin
candid
thu
vlp
produc
recombin
system
anticip
promin
among
approach
commerci
suv
